Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALZ-101 in Early Alzheimer's Disease
NCT05328115Phase 1Completed
- Sponsor
- Alzinova AB
- Start
- Sep 2021
- Primary completion
- Jan 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALZ-101 in Alzheimer's disease (AD) (4 arms), sponsored by Alzinova AB. Primary endpoints: Number of adverse events (AEs) and serious AEs (SAEs) at 1 year, Number of participants with treatment-emergent AEs and SAEs at 1 year and 2 more. Started Sep 2021; status: completed.
02
Drugs
ALZ-101
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05328115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05328115.